Omeros Corporation – NASDAQ:OMER
Founder-led company
Omeros stock price today
$4.37
-7.31
-62.59%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Omeros stock price monthly change
+173.54%
month
Omeros stock price quarterly change
+173.54%
quarter
Omeros stock price yearly change
+258.28%
year
Omeros key metrics
Market Cap | 582.39M |
Enterprise value | 687.50M |
P/E | -1.82 |
EV/Sales | N/A |
EV/EBITDA | 9.67 |
Price/Sales | N/A |
Price/Book | 4.16 |
PEG ratio | 0.02 |
EPS | -1.96 |
Revenue | N/A |
EBITDA | -162.57M |
Income | -121.29M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOmeros stock price history
Omeros stock forecast
Omeros financial statements
| Jun 2023 | 0 | -37.29M | |
|---|---|---|---|
| Sep 2023 | 0 | -37.75M | |
| Dec 2023 | 1.36M | -9.06M | -663.84% |
| Mar 2024 | 0 | -37.18M |
| 2025 | 76.75M | 10.05M | 13.09% |
|---|---|---|---|
| 2026 | 80.2M | 10.85M | 13.53% |
| 2027 | 46M | -82.37M | -179.09% |
| 2028 | 157M | 13.80M | 8.79% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 527421000 | 506.91M | 96.11% |
|---|---|---|---|
| Sep 2023 | 493071000 | 507.02M | 102.83% |
| Dec 2023 | 378269000 | 403.25M | 106.6% |
| Mar 2024 | 437492000 | 508.82M | 116.3% |
| Jun 2023 | -32.34M | 35.37M | -260K |
|---|---|---|---|
| Sep 2023 | -32.64M | 57.16M | -483K |
| Dec 2023 | -34.82M | 116.24M | -104.95M |
| Mar 2024 | -41.78M | -61.92M | 98.43M |
Omeros alternative data
| Aug 2023 | 196 |
|---|---|
| Sep 2023 | 196 |
| Oct 2023 | 196 |
| Nov 2023 | 196 |
| Dec 2023 | 196 |
| Jan 2024 | 196 |
| Feb 2024 | 196 |
| Mar 2024 | 196 |
| Apr 2024 | 196 |
| May 2024 | 198 |
| Jun 2024 | 198 |
| Jul 2024 | 198 |
Omeros other data
17.94%
-14.75%
of OMER is owned by hedge funds
57
-39
11.25M
-9.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 0 | 10000 |
| Nov 2023 | 25000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | DEMOPULOS GREGORY A MD officer: Chairman.. | Common Stock | 15,000 | $1.68 | $25,200 | ||
Purchase | DEMOPULOS PETER A MD director | Common Stock | 10,000 | $1.53 | $15,300 | ||
Option | HANISH ARNOLD C director | Stock Option (Right to Buy) | 5,000 | $5.3 | $26,500 | ||
Option | HANISH ARNOLD C director | Common Stock | 5,000 | $5.3 | $26,500 | ||
Sale | HANISH ARNOLD C director | Common Stock | 5,000 | $6.46 | $32,300 | ||
Option | CABLE THOMAS J. director | Common Stock | 5,000 | $5.3 | $26,500 | ||
Sale | CABLE THOMAS J. director | Common Stock | 5,000 | $6.53 | $32,650 | ||
Option | CABLE THOMAS J. director | Stock Option (Right to Buy) | 5,000 | $5.3 | $26,500 | ||
Option | HANISH ARNOLD C director | Common Stock | 10,000 | $9.44 | $94,400 | ||
Option | HANISH ARNOLD C director | Stock Option (Right to Buy) | 10,000 | $9.44 | $94,400 |
| Patent |
|---|
Application Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders Filling date: 11 Oct 2021 Issue date: 18 Aug 2022 |
Application Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria Filling date: 11 Oct 2021 Issue date: 4 Aug 2022 |
Application Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions Filling date: 17 Dec 2021 Issue date: 9 Jun 2022 |
Application Filling date: 15 Dec 2021 Issue date: 9 Jun 2022 |
Application Filling date: 9 Sep 2021 Issue date: 24 Mar 2022 |
Application Filling date: 18 Nov 2021 Issue date: 3 Mar 2022 |
Application CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES Filling date: 11 Nov 2021 Issue date: 3 Mar 2022 |
Application Filling date: 17 Aug 2021 Issue date: 24 Feb 2022 |
Grant Utility: Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions Filling date: 14 Feb 2019 Issue date: 1 Feb 2022 |
Application Filling date: 9 Jul 2021 Issue date: 6 Jan 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 1 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
Omeros: Why It Is Worthwhile To Bet On Narsoplimab
Omeros: Betting Big On Narsoplimab, We Are Still A Buyer
Omeros Corporation - Still Looking Too Risky For A Buy Rating
Omeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023
Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy
Omeros: Worst Has Been Priced In, We Like Its IgAN Pipeline, Initiating With A Buy
Vera: Disappointing Data From Phase 2 ORIGIN Trial, Initiating Coverage With A Sell Rating
Omeros' Deafening Silence
Omeros: FDA Appeal On Narsoplimab And Several 2023 Catalysts On Deck
-
What's the price of Omeros stock today?
One share of Omeros stock can currently be purchased for approximately $4.37.
-
When is Omeros's next earnings date?
Unfortunately, Omeros's (OMER) next earnings date is currently unknown.
-
Does Omeros pay dividends?
No, Omeros does not pay dividends.
-
How much money does Omeros make?
Omeros has a market capitalization of 582.39M.
-
What is Omeros's stock symbol?
Omeros Corporation is traded on the NASDAQ under the ticker symbol "OMER".
-
What is Omeros's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Omeros?
Shares of Omeros can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Omeros's key executives?
Omeros's management team includes the following people:
- Dr. Gregory A. Demopulos Co-Founder, Chairman, Chief Executive Officer & Pres(age: 66, pay: $2,240,000)
- Mr. Michael A. Jacobsen Chief Accounting Officer, Vice President of Fin. & Treasurer(age: 67, pay: $543,750)
- Mr. Peter B. Cancelmo J.D. Vice President, Gen. Counsel & Corporation Sec.(age: 46, pay: $409,110)
-
Is Omeros founder-led company?
Yes, Omeros is a company led by its founder Dr. Gregory A. Demopulos.
-
How many employees does Omeros have?
As Jul 2024, Omeros employs 198 workers, which is 1% more then previous quarter.
-
When Omeros went public?
Omeros Corporation is publicly traded company for more then 15 years since IPO on 8 Oct 2009.
-
What is Omeros's official website?
The official website for Omeros is omeros.com.
-
Where are Omeros's headquarters?
Omeros is headquartered at The Omeros Building, Seattle, WA.
-
How can i contact Omeros?
Omeros's mailing address is The Omeros Building, Seattle, WA and company can be reached via phone at +20 66 765000.
Omeros company profile:
Omeros Corporation
omeros.comExchange:
NASDAQ
Full time employees:
198
Industry:
Biotechnology
Sector:
Healthcare
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
The Omeros Building
Seattle, WA 98119
Seattle, WA 98119
CIK: 0001285819
ISIN: US6821431029
CUSIP: 682143102
